| Q95300330 | 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer |
| Q42700424 | A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer |
| Q64064828 | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| Q34550256 | A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland. |
| Q41691950 | A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer |
| Q39195814 | A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells |
| Q89389032 | A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer |
| Q37297350 | A hormone-DNA repair circuit governs the response to genotoxic insult |
| Q35248192 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer |
| Q90282411 | A novel transcriptional network for the androgen receptor in human epididymis epithelial cells |
| Q39124486 | A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. |
| Q27853127 | A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer |
| Q98947294 | ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers |
| Q35600629 | AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis |
| Q37337217 | Advances in androgen receptor targeted therapy for prostate cancer |
| Q34042831 | Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer |
| Q37508596 | Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| Q35853865 | Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. |
| Q38829510 | An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells |
| Q92410955 | Androgen Receptor Dependence |
| Q38673660 | Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer |
| Q39227656 | Androgen Signaling in Prostate Cancer |
| Q26748844 | Androgen control of lipid metabolism in prostate cancer: novel insights and future applications |
| Q92783151 | Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer |
| Q26866135 | Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases |
| Q37688544 | Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo |
| Q33922393 | Androgen receptor functions in prostate cancer development and progression |
| Q42880656 | Androgen receptor genomic regulation |
| Q40493333 | Androgen receptor profiling predicts prostate cancer outcome |
| Q34786508 | Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9 |
| Q39096880 | Androgen receptor signaling regulates DNA repair in prostate cancers |
| Q47197872 | Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer |
| Q30577613 | Androgen receptor splice variants determine taxane sensitivity in prostate cancer |
| Q37709535 | Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles |
| Q33663401 | Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element |
| Q57800002 | Androgen-dependent immune modulation in parasitic infection |
| Q35543453 | Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells |
| Q37294780 | BAP18 coactivates androgen receptor action and promotes prostate cancer progression. |
| Q36069139 | CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells |
| Q24311817 | CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2 |
| Q57114753 | Carcinogenesis in prostate cancer: The role of long non-coding RNAs |
| Q38728375 | Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. |
| Q40565537 | Cell cycle-coupled expansion of AR activity promotes cancer progression. |
| Q92316366 | Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications |
| Q38851252 | ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions |
| Q48112811 | Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. |
| Q36849142 | Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target |
| Q90287857 | Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers |
| Q37533894 | Comprehensive functional annotation of 77 prostate cancer risk loci |
| Q34775572 | Constitutive activity of the androgen receptor |
| Q39164084 | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| Q27009437 | Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response |
| Q93132706 | Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11 |
| Q46068832 | Differential impact of RB status on E2F1 reprogramming in human cancer |
| Q38260830 | Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. |
| Q58116001 | Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer |
| Q39178242 | ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients |
| Q33733903 | Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype |
| Q35097917 | Epidaurus: aggregation and integration analysis of prostate cancer epigenome |
| Q46885929 | Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. |
| Q37139070 | Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer |
| Q90104464 | Factors that influence the androgen receptor cistrome in benign and malignant prostate cells |
| Q92514369 | Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor |
| Q42318949 | Gene regulation: Long RNAs wire up cancer growth |
| Q92213930 | Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development |
| Q39376859 | Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets. |
| Q36952878 | Global profiling of prolactin-modulated transcripts in breast cancer in vivo. |
| Q38757500 | Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability |
| Q38923075 | HES5 silencing is an early and recurrent change in prostate tumourigenesis |
| Q33623369 | HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network |
| Q33962848 | Histone H2A.Z deregulation in prostate cancer. Cause or effect? |
| Q91808463 | How Prostate Cancer Cells Use Strategy Instead of Brute Force to Achieve Metastasis |
| Q41554763 | ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells |
| Q97681497 | Identification of long non-coding RNAs in advanced prostate cancer associated with androgen receptor splicing factors |
| Q92901971 | Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer |
| Q34577355 | Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework. |
| Q39364217 | Incorporating Functional Annotations for Fine-Mapping Causal Variants in a Bayesian Framework Using Summary Statistics. |
| Q90631958 | Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways |
| Q58772565 | Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway |
| Q39683347 | Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome |
| Q36106271 | Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study |
| Q36065460 | Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions |
| Q59336239 | Integrative epigenetic taxonomy of primary prostate cancer |
| Q36413695 | Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor |
| Q59333350 | Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy |
| Q37258836 | KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis |
| Q98499631 | LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression |
| Q36004694 | Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer |
| Q33888770 | Lipid degradation promotes prostate cancer cell survival |
| Q59051399 | Looking beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer |
| Q35573029 | Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis |
| Q38190362 | Maintaining and reprogramming genomic androgen receptor activity in prostate cancer |
| Q39720967 | Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing |
| Q34497810 | MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators |
| Q41136545 | MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q37225156 | Molecular signatures in urologic tumors |
| Q35646703 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans |
| Q33701352 | NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. |
| Q42878519 | Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR. |
| Q30847259 | Network analysis of ChIP-Seq data reveals key genes in prostate cancer |
| Q57107495 | New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors |
| Q39093621 | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| Q38384489 | Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment |
| Q26774456 | Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism |
| Q51019461 | Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. |
| Q44582971 | Novel preclinical models and biomarkers for prostate cancer |
| Q47104606 | Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer |
| Q47217714 | Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. |
| Q93382033 | ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis |
| Q26740548 | One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling |
| Q60928414 | Optimized ChIP-seq method facilitates transcription factor profiling in human tumors |
| Q38714374 | Patient-derived xenografts as in vivo models for research in urological malignancies |
| Q37592443 | Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer. |
| Q30361019 | Prognostic Significance and Functional Role of CEP57 in Prostate Cancer |
| Q36469793 | Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites |
| Q37270422 | ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer |
| Q39342369 | Rationale for the development of alternative forms of androgen deprivation therapy |
| Q50068799 | Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. |
| Q28607387 | Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man |
| Q36590632 | Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival |
| Q36578330 | Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action |
| Q35897569 | Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks |
| Q38265572 | Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. |
| Q38736287 | Role of steroid receptor and coregulator mutations in hormone-dependent cancers |
| Q110013316 | SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism |
| Q36888336 | STAT5A/B gene locus undergoes amplification during human prostate cancer progression |
| Q38979379 | SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. |
| Q37582591 | Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships |
| Q97533909 | Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer |
| Q37705831 | Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures |
| Q39016544 | Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer |
| Q38950688 | TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer |
| Q39986242 | Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. |
| Q36347511 | Targeting Transcription Factors in Cancer |
| Q90059156 | Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy |
| Q33775717 | Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? |
| Q93105571 | Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy |
| Q38323902 | Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer |
| Q38132057 | The '-omics' revolution and oesophageal adenocarcinoma |
| Q97531381 | The DNA methylation landscape of advanced prostate cancer |
| Q33698635 | The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer |
| Q37051378 | The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer |
| Q37009376 | The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. |
| Q40393450 | The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. |
| Q30370955 | The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 |
| Q36449325 | The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis |
| Q38259961 | The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. |
| Q104486604 | The androgen receptor expression and its activity have different relationships with prognosis in hepatocellular carcinoma |
| Q37610075 | The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples |
| Q35039889 | The biology of castration-resistant prostate cancer |
| Q38965060 | The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells |
| Q35876533 | The co-chaperone p23 promotes prostate cancer motility and metastasis |
| Q35548366 | The evolutionary history of lethal metastatic prostate cancer |
| Q26767112 | The first decade of estrogen receptor cistromics in breast cancer |
| Q38109474 | The genomic landscape of prostate cancer |
| Q38903008 | The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo |
| Q41963995 | The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study |
| Q38811520 | The role of glycans in the development and progression of prostate cancer |
| Q38119251 | The role of the androgen receptor in triple-negative breast cancer |
| Q38140106 | The transcriptional programme of the androgen receptor (AR) in prostate cancer |
| Q37084432 | The ubiquitin ligase Siah2 is revealed as an accomplice of the androgen receptor in castration resistant prostate cancer |
| Q37676253 | Therapeutic Approaches Targeting MYC-Driven Prostate Cancer |
| Q37707477 | Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs |
| Q33699091 | Transcription factors involved in prostate gland adaptation to androgen deprivation |
| Q35611347 | Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer |
| Q39066491 | USP22 regulates oncogenic signaling pathways to drive lethal cancer progression |
| Q60919122 | Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer |